Table 4.
Antimicrobial resistance of GPB isolated from cancer patients at the University of Gondar Hospital, Northwest Ethiopia, 2017
| Antimicrobial tested | GPB isolates, N (%)
|
||||
|---|---|---|---|---|---|
| Staphylococcus aureus (n=12) | CoNS (n=11) | Enterococci spp. (n=2) | Total | ||
|
| |||||
| Ciprofloxacin | 1 (8.3) | 5 (45.5) | 1 (50.0) | 7 (28.0) | |
| Gentamycin | 1 (8.3) | 4 (36.4) | – | 5 (21.7) | |
| Nitrofurantoin | 0 | 0 | 1 (50) | 1 (5.6) | |
| Norfloxacin | 0 | 2 (22.2) | 1 (50) | 3 (16.7) | |
| Cot-trimoxazole | 5 (41.7) | 5 (45.5) | – | 10 (43.5) | |
| Penicillin | 7 (58.3) | 10 (90.9) | 1 (50) | 18 (72.0) | |
| Vancomycin | – | – | 1 (50) | 1 (50) | |
| Cefoxitin | 3 (25.0) | 5 (45.5) | – | 8 (34.8) | |
| Tetracycline | 3 (60) | 1 (50) | 1 (50) | 5 (20.0) | |
Abbreviations: GPB, gram-positive bacterial; CoNS, coagulase negative staphylococci.